Detailed Narrative
Strong Q2 FY25 Performance Driven by Capacity Expansion
Blue Jet Healthcare delivered a robust Q2 FY25, with turnover reaching ₹207.1 crores, marking a 28% sequential and 18% year-on-year growth. This strong performance translated into a record-high quarterly PAT of ₹58.3 crores, representing 28% of total revenues and a 22% YoY increase. The company also reported a healthy EBITDA of ₹69.5 crores, up 11% YoY, and maintained a debt-free status with ₹323.3 crores in liquidity as of September 2024.
Strategic Capacity Additions and Commercialization Milestones
The company successfully commissioned Plant 6 at Unit 2 Ambernath, adding 120 KL of capacity at a cost of ₹90 crores, primarily for PI and contrast media segments. Commercial production for a key cardiovascular therapy client commenced in mid-September, with optimal utilization anticipated by Q3-Q4 FY25. Additionally, validation batches for an advanced intermediate in the MRI space are ongoing, with commercial supplies expected to begin in Q3 FY25.
H1 FY25 Performance and Segmental Dynamics
For the first half of FY25, Blue Jet Healthcare reported a turnover of ₹371.1 crores, a 3% increase YoY, and a PAT of ₹96.1 crores, up 4.5% YoY. While the contrast media segment saw a 31% de-growth in H1 FY25 to ₹177.9 crores, attributed to lower customer off-take and Red Sea transit delays, the pharmaceutical intermediate segment surged by 282% to ₹119.8 crores. The artificial sweetness segment maintained stable turnover at approximately ₹60 crores.
Addressing Red Sea Impact and Revenue Recognition
Management clarified that Red Sea issues have prolonged transit times from 30-35 days to 55-60 days, impacting revenue recognition. Approximately ₹60-70 crores of revenue, predominantly from contrast media, were delayed from Q1/H1 and are expected to be recognized in Q3. Despite these delays, the company expects contrast media demand to stabilize from Q4 FY25 and aims to achieve full-year volumes comparable to the previous year.
R&D Focus on Enzymatic Chemistry and Pipeline Expansion
Blue Jet Healthcare is actively expanding its R&D capabilities, having doubled its R&D hardware and scientific talent pool in the last 12 months. The company is exploring new chemistry platforms, including enzymatic processes, which offer advantages in chiral selection and significantly lower effluent generation (1:50 ratio). Management indicated that commercialization of products from enzymatic chemistry is 'very close' and could commence as early as next year, targeting both general products and CDMO opportunities.
Capex Plans and Long-Term Growth Outlook
The company's capital expenditure plans remain on track, with an annual guidance of ₹200 crores. Beyond Plant 6, Blue Jet is developing a small volume plant at Unit 2 for Q1 FY26 commissioning, aimed at proof-of-concept and GMP validation. Unit 3 at Mahad is also being developed for backward integration in contrast media, with commissioning targeted for Q1 FY26, supporting the company's long-term strategic independence and cost leadership goals.